Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, Julphar, said the sale of this facility is a further step in Julphar’s strategy to divest non-core assets. Hocine Sidi Said, CEO of KELIX bio, ...

Kelix bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec, a subsidiary of Julphar. This acquisition strengthens Mubadala's ...

The vaccine has been developed by the Hualan Biological Bacterin Company of China and will be mass produced in the UAE by the Gulf Pharmaceutical Industries (Julphar) headquartered in Ras Al Khaimah.

Gulf Pharmaceutical Industries (Julphar) has announced the signing of an exclusive license and production agreement with Quantum Genomics, a leading biopharmaceutical company specializing in the ...